NeuroHagana
Preventing Permanent Disabilities after Neurotrauma
Company Overview
Snapshot
Founded in March 2023 by Angela Ruban, NeuroHagana operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing an emergency treatment for neurotrauma. In May 2025, NeuroHagana was selected to join the SCI Incubate 2025 Cohort by the Praxis Spinal Cord Institute.
Business overview
NeuroHagana (NH) is a Health Tech & Life Sciences company specializing in the development of an injectable emergency treatment for neurotrauma, designed to prevent permanent disabilities. Its core technology targets glutamate excitotoxicity, a primary factor in neurotrauma pathology, by reducing excessive glutamate levels in the Central Nervous System to prevent irreversible neuronal damage. The company's products, including emergency treatments for Spinal Cord Injury and Traumatic Brain Injury, are in the R&D stage and are intended for markets such as Europe and the USA, serving paramedics, hospital trauma units, first aid teams, and military forces.
Strategic signal
In May 2025, NeuroHagana was selected to join the SCI Incubate 2025 Cohort by the Praxis Spinal Cord Institute. This inclusion signals significant validation for NeuroHagana's innovative approach to treating spinal cord injuries and provides access to specialized resources and expertise, accelerating its development and market entry within the neurotrauma treatment landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is NeuroHagana's primary focus?
- NeuroHagana is focused on developing an injectable emergency treatment for neurotrauma, aiming to prevent permanent disabilities by addressing glutamate excitotoxicity.
- When was NeuroHagana founded?
- NeuroHagana was founded in March 2023.
- Who is the founder of NeuroHagana?
- Angela Ruban is the Co-founder & CEO of NeuroHagana.
- What significant program did NeuroHagana join in May 2025?
- In May 2025, NeuroHagana was selected to join the SCI Incubate 2025 Cohort by the Praxis Spinal Cord Institute.
- What markets does NeuroHagana target for its initial applications?
- NeuroHagana's initial applications for its emergency treatment for Spinal Cord Injury are targeted towards Europe and the USA.